US Patent Board To Review Mylan's Copaxone Challenge

The U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) proceedings for petitions filed by Mylan against two patents held by Teva on its moneymaker multiple sclerosis drug Copaxone (glatiramer acetate injection).

The U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) proceedings for petitions filed by Mylan against two patents held by Teva on its moneymaker multiple sclerosis drug Copaxone (glatiramer acetate injection).

The PTAB said there is a "reasonable likelihood" Mylan would prevail in its challenges against Teva's patents, known as '250...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category